Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Triple Negative Breast Neoplasms 4Colorectal Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Melanoma 2Lung Neoplasms 2Head and Neck Neoplasms 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Thymus Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Radiotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-Negative Locally Advanced Breast Cancer × Immunotherapy × Breast × Clear all
NCT06908668 2025-04-03

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
170 enrolled
Breast

HER2-Negative Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡